A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

August 31, 2016

Conditions
Squamous Cell Carcinoma of the Oral CavitySquamous Cell Carcinoma of the Oropharynx
Interventions
DRUG

GC4419

GC4419 is a novel, highly stable manganese-containing macrocyclic ligand complex with a molecular weight of 483, whose activity mimics that of naturally occurring superoxide dismutase (SOD) enzymes. It is therefore a prototype of a new class of drugs termed selective SOD mimetics. GC4419 selectively removes superoxide anions without reacting with other reactive oxygen species, including nitric oxide, hydrogen peroxide, and peroxynitrite.

Trial Locations (10)

14642

University of Rochester Medical Center, Rochester

15212

Allegheny General Hospital, Pittsburgh

18045

St. Luke's Cancer Center, Easton

27157

Wake Forest Baptist Health, Winston-Salem

33805

Lakeland Regional Cancer Center, Lakeland

44304

Summa Health System- Cooper Cancer Center, Akron

52242

University of Iowa, Iowa City

63110

Washington University School of Medicine, St Louis

68198

University of Nebraska Medical Center, Omaha

99216

Cancer Care Northwest, Spokane

Sponsors
All Listed Sponsors
lead

Galera Therapeutics, Inc.

INDUSTRY

NCT01921426 - A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck | Biotech Hunter | Biotech Hunter